Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-10

As has been stated by the company in at least two announcements, inlcluding in this qly, the trial will definitely not be halted while the safety review is in progress...

"The first data review meeting occurred in April after the first 5 subjects were dosed in the trial with no drug related adverse events reported (ASX announcement dated 29 April, 2024). Subsequent patient safety reviews by the DSMB are scheduled at least every six months, subject to recruitment rates, with meetings to be held post dosing of 23 patients, 46 patients, 69 patients, and at the completion of dosing of all 92 patients. Trial enrolment will not be halted during each planned DSMB review of the safety data. With 25% of patient recruitment now completed, the DSMB will meet at the end of Q3 CY2024 to determine whether there are any safety issues and determine whether the trial can continue under the current study protocol."